Breast Cancer: A Study Explains How DHA Affects Inflammation

A newly published study in the oncology journal Cancer brings hope in the fight against breast cancer. According to researchers at La Sapienza University in Rome – the authors of the study – omega-3 DHA derived from algae may play a crucial role in reducing the inflammation that contributes to cancer development.

The study is titled: “Effects of Oral DHA Supplementation on Plasma Levels of Resolvin D1 and D2 in Untreated Breast Cancer Patients” (read the full study here).

The introduction notes: “Breast cancer is often associated with a state of chronic inflammation. […] Certain molecules called resolvins, naturally produced by the body from omega-3 fatty acids such as DHA, are involved in resolving systemic inflammation and may have anti-tumour properties.”

How DHA Works on Inflammation

Supplemental intake of omega-3 – specifically DHA from algal oil – encourages the body to produce specialised molecules (resolvins) that actively reduce inflammation. Unlike traditional anti-inflammatories, resolvins do not merely block inflammation, but selectively regulate the processes involved.

DHA and Inflammation Resolution in Cancer

In the context of cancer, where inflammation is often chronic, modulating these mechanisms through omega-3 DHA could represent a promising therapeutic approach.
The groundbreaking findings of this study shed light on the potential role of resolvins in resolving breast cancer and how they may interact with tumour characteristics influenced by oral omega-3 DHA intake.

Incidence and Importance of Prevention

According to 2022 data, 2.3 million women worldwide are diagnosed with breast cancer each year.
In addition to conventional medical treatments, the most effective strategies continue to be early diagnosis, preventive measures, a healthy lifestyle and a balanced diet.

Study Results

The official report states: “This study investigated whether oral DHA supplementation could alter the levels of two types of resolvins – RvD1 and RvD2 – in women recently diagnosed with breast cancer. It found that women with BRCA1 or BRCA2 gene mutations showed the most significant increase in these molecules after supplementation, suggesting a stronger anti-inflammatory response. In contrast, women with a family history of breast cancer but without genetic mutations showed a decrease in RvD1.”